Stability of colistimethate sodium in aqueous solution

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6432-6433

  Healan, A M ^a   Gray, W ^b   Fuchs, E J ^c   Griffiss, J M ^d   Salata, R A ^a   Blumer, J ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Clinical RM ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN;

AQUEOUS SOLUTION; ARTICLE; DRUG STABILITY; DRUG STORAGE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; COLISTIN; DRUG COMPOUNDING; DRUG STABILITY; PHARMACEUTICAL SOLUTIONS; TANDEM MASS SPECTROMETRY; TEMPERATURE; WATER;

EID: 84869219110     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01079-12     Document Type: Article

References (11)

1. Dudhani RV, Nation R, Li J. 2010. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J. Antimicrob. Chemother. 65:1412-1415.
2. FDA. 2007. Public health advisory: colistimethate (marked as Coly-Mycin M and generic products). FDA, Silver Spring, MD.
3. Le J, et al. 2010. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 30:562-584.
4. Li J, et al. 2003. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52:987-992.
5. Li J, Milne R, Nation R, Turnidge J, Coulthard K. 2003. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob. Agents Chemother. 47:1364-1370.
6. Lim L, et al. 2010. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30:1279-1291.
7. Michalopoulos A, Papadakis E. 2010. Inhaled anti-infective agents: emphasis on colistin. Infection 38:81-88.
8. Reed M, Stern R, O'Riordan M, Blumer J. 2001. The pharmacokinetics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol. 41:645-654.
9. Santamaria C, et al. 2009. Nephrotoxicity associated with the use of intravenous colistin. Scand. J. Infect. Dis. Suppl. 41:767-769.
10. Song J. 2011. Colistimethate: risk of serious or fatal medication error. Infect. Dis. Alert 30:121-124.
11. Wallace S, Li J, Rayner C, Coulthard K, Nation R. 2008. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob. Agents Chemother. 52:3047-3051.